Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model

Cancer Research

Volumn 67, Issue 4, 2007, Pages 1744-1749

  Takeda, Takayuki ^a,b   Hattori, Noboru ^a   Tokuhara, Takahiro ^a   Nishimura, Yoshihiro ^b   Yokoyama, Mitsuhiro ^b   Miyake, Masayuki ^a  

^a Kitano Hospital   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD82 ANTIGEN; CD9 ANTIGEN; COMPLEMENTARY DNA; TETRASPANIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG INHIBITION; GENE TARGETING; GENE TRANSFER; GENETIC CODE; LACZ GENE; LUNG CARCINOMA; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; OPERON; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; KANGAI-1 PROTEIN; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEMBRANE GLYCOPROTEINS; MICE; TRANSDUCTION, GENETIC;

EID: 33847738889     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3090     Document Type: Article

References (31)

1. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997;80:1529-37.
2. Ahmad A, Hart IR. Mechanisms of metastasis. Crit Rev Oncol Hematol 1997;26:163-73.
3. Boyd D. Invasion and metastasis. Cancer Metastasis Rev 1996;15:77-89.
4. DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 1997;425:89-97.
5. Denhardt DT. Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Crit Rev Oncog 1996;7:261-91.
6. Miyake M, Koyama M, Seno M, Ikeyama S. Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med 1991;174:1347-54.
7. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268:884-6.
8. Huang CL, Taki T, Adachi M, et al. MRP-1/CD9 and KAI1/CD82 expression in normal and various cancer tissues. Int J Oncol 1997;11:1045-51.
9. Miyamoto S, Maruyama A, Okugawa K, et al. Loss of motility-related protein 1 (MRP1/CD9) and integrin α3 expression in endometrial cancers. Cancer 2001;92:542-8.
10. Hashida H, Takabayashi A, Tokuhara T, et al. Integrin α3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. Int J Cancer 2002;97:518-25.
11. Dong JT, Suzuki H, Pin SS, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996;56:4387-90.
12. Miyake M, Nakano K, Ieki Y, et al. Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res 1995;55:4127-31.
13. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M, Miyake M. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996;56:1751-5.
14. Cajot JF, Sordat I, Silvestre T, Sordat B. Differential display cloning identifies motility-related protein (MRP-1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res 1997;57:2593-7.
15. Higashiyama M, Taki T, Ieki Y, et al. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 1995;55:6040-4.
16. Higashiyama M, Kodama K, Yokouchi H, et al. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunonistochemical analysis. Cancer 1998;83:466-74.
17. Miyake M, Nakano K, Itoi SI, Koh T, Taki T. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 1996;56:1244-9.
18. Miyake M, Adachi M, Huang C, Higashiyama M, Kodama K, Taki T. A novel molecular staging protocol for non-small cell lung cancer. Oncogene 1999;18:2397-404.
19. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993;177:1231-7.
20. Takaoka A, Hinoda Y, Sato S, et al. Reduced invasive and metastatic potentials of KAI1-transfected melanoma cells. Jpn J Cancer Res 1998;89:397-404.
21. Miyake M, Inufusa H, Adachi M, et al. Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery. Oncogene 2000;19:5221-6.
22. Imai T, Fukudome K, Takagi S, et al. C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J Immunol 1992;149:2879-86.
23. Doki Y, Murakami K, Yamaura T, Sugiyama S, Misaki T, Saiki I. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer 1999;79:1121-6.
24. Mastrangeli A, Danel C, Rosenfeld MA, et al. Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. J Clin Invest 1993;91:225-34.
25. Gregory LG, Harbottle RP, Lawrence L, Knapton HJ, Themis M, Coutelle C. Enhancement of adenovirus-mediated gene transfer to the airways by DEAE dextran and sodium caprate in vivo. Mol Ther 2003;7:19-26.
26. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995;110:601-5.
27. van Velzen E, Snijder RJ, Brutel de la Riviere A, Elbers HJ, van den Bosch JM. Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases. Chest 1996;110:1469-73.
28. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-23.
29. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003;10:955-63.
30. Jenkins RG, McAnulty RJ, Hart SL, Laurent GJ. Pulmonary gene therapy. Realistic hope for the future, or false dawn in the promised land? Monaldi Arch Chest Dis 2003;59:17-24.
31. Koto M, Miyamoto T, Yamamoto N, Nishimura H, Yamada S, Tsujii H. Local control and recurrence of stage I non-small cell lung cancer after carbon ion radiotherapy. Radiother Oncol 2004;71:147-56.